NL8602140A - Werkwijze voor het verhinderen van een hypotensieve shock en gelokaliseerde botresorptie veroorzaakt door bacteriele endotoxinen. - Google Patents

Werkwijze voor het verhinderen van een hypotensieve shock en gelokaliseerde botresorptie veroorzaakt door bacteriele endotoxinen. Download PDF

Info

Publication number: NL8602140A
Authority: NL; Netherlands
Prior art keywords: endotoxin; peroxy; diphosphate compound; compound; peroxy diphosphate
Prior art date: 1985-08-22

Application number

NL8602140A

Other languages

English (en)

Dutch (nl)

Original Assignee

Colgate Palmolive Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-08-22

Filing date

1986-08-22

Publication date

1987-03-16

1986-08-22 Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co

1987-03-16 Publication of NL8602140A publication Critical patent/NL8602140A/nl

Links

239000002158 endotoxin Substances 0.000 title claims description 63
238000000034 method Methods 0.000 title claims description 18
208000006386 Bone Resorption Diseases 0.000 title claims description 10
230000024279 bone resorption Effects 0.000 title claims description 10
208000001953 Hypotension Diseases 0.000 title claims description 6
208000021822 hypotensive Diseases 0.000 title claims description 6
230000001077 hypotensive effect Effects 0.000 title claims description 6
230000035939 shock Effects 0.000 title claims description 6
-1 peroxy diphosphate compound Chemical class 0.000 claims description 27
239000001177 diphosphate Substances 0.000 claims description 21
235000011180 diphosphates Nutrition 0.000 claims description 20
150000001875 compounds Chemical class 0.000 claims description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
231100000252 nontoxic Toxicity 0.000 claims description 7
230000003000 nontoxic effect Effects 0.000 claims description 7
150000002148 esters Chemical class 0.000 claims description 6
239000008187 granular material Substances 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
125000001417 5'-guanylyl group Chemical group C=12N=C(N([H])[H])N([H])C(=O)C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 5
241001465754 Metazoa Species 0.000 claims description 5
238000000576 coating method Methods 0.000 claims description 5
125000001572 5'-adenylyl group Chemical group C=12N=C([H])N=C(N([H])[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 claims description 4
230000037396 body weight Effects 0.000 claims description 4
239000011248 coating agent Substances 0.000 claims description 4
239000011780 sodium chloride Substances 0.000 claims description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 3
229910052783 alkali metal Inorganic materials 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
229910019142 PO4 Inorganic materials 0.000 claims description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
150000001340 alkali metals Chemical class 0.000 claims description 2
239000012153 distilled water Substances 0.000 claims description 2
239000012530 fluid Substances 0.000 claims description 2
230000000415 inactivating effect Effects 0.000 claims description 2
230000002779 inactivation Effects 0.000 claims description 2
230000000968 intestinal effect Effects 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
239000010452 phosphate Substances 0.000 claims description 2
239000002510 pyrogen Substances 0.000 claims description 2
125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
229910052718 tin Inorganic materials 0.000 claims description 2
229910052725 zinc Inorganic materials 0.000 claims description 2
239000011701 zinc Substances 0.000 claims description 2
125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
210000002784 stomach Anatomy 0.000 claims 1
239000011135 tin Substances 0.000 claims 1
210000002966 serum Anatomy 0.000 description 17
230000035605 chemotaxis Effects 0.000 description 15
239000000243 solution Substances 0.000 description 12
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
239000001301 oxygen Substances 0.000 description 11
229910052760 oxygen Inorganic materials 0.000 description 11
210000000988 bone and bone Anatomy 0.000 description 10
230000000694 effects Effects 0.000 description 8
238000011282 treatment Methods 0.000 description 7
241000700159 Rattus Species 0.000 description 5
239000000463 material Substances 0.000 description 5
239000002609 medium Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
231100000331 toxic Toxicity 0.000 description 5
230000002588 toxic effect Effects 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000002904 solvent Substances 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
239000011575 calcium Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
210000000214 mouth Anatomy 0.000 description 3
239000007787 solid Substances 0.000 description 3
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
102000013563 Acid Phosphatase Human genes 0.000 description 2
108010051457 Acid Phosphatase Proteins 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000012267 brine Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000003399 chemotactic effect Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
230000037406 food intake Effects 0.000 description 2
210000004211 gastric acid Anatomy 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000003200 peritoneal cavity Anatomy 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
241000606750 Actinobacillus Species 0.000 description 1
208000002679 Alveolar Bone Loss Diseases 0.000 description 1
241000606125 Bacteroides Species 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
150000001767 cationic compounds Chemical class 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
210000003837 chick embryo Anatomy 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000002498 deadly effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000007893 endotoxin activity Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000006260 foam Substances 0.000 description 1
OKISBDHRUPZLOC-UHFFFAOYSA-N gallin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C(O)=C2OC2=C(O)C(O)=CC=C21 OKISBDHRUPZLOC-UHFFFAOYSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910001411 inorganic cation Inorganic materials 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
230000006651 lactation Effects 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
230000011268 leukocyte chemotaxis Effects 0.000 description 1
238000012454 limulus amebocyte lysate test Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000009965 odorless effect Effects 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
150000002895 organic esters Chemical group 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
150000004971 peroxyphosphoric acids Chemical class 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
229910052712 strontium Inorganic materials 0.000 description 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000000606 toothpaste Substances 0.000 description 1
210000000623 ulna Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NL8602140A 1985-08-22 1986-08-22 Werkwijze voor het verhinderen van een hypotensieve shock en gelokaliseerde botresorptie veroorzaakt door bacteriele endotoxinen. NL8602140A (nl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US76839685A	1985-08-22	1985-08-22
US76839685		1985-08-22
US85191586A	1986-04-14	1986-04-14
US85191586		1986-04-14

Publications (1)

Publication Number	Publication Date
NL8602140A true NL8602140A (nl)	1987-03-16

Family

ID=27118049

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8602140A NL8602140A (nl)	1985-08-22	1986-08-22	Werkwijze voor het verhinderen van een hypotensieve shock en gelokaliseerde botresorptie veroorzaakt door bacteriele endotoxinen.

Country Status (12)

Country	Link
BE (1)	BE905319A (fr)
CA (1)	CA1282004C (fr)
CH (1)	CH670046A5 (fr)
DE (1)	DE3627759A1 (fr)
DK (1)	DK168513B1 (fr)
FR (1)	FR2586351B1 (fr)
GB (1)	GB2180451B (fr)
HK (1)	HK593A (fr)
IT (1)	IT1196587B (fr)
NL (1)	NL8602140A (fr)
SE (1)	SE468626B (fr)
SG (1)	SG108892G (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2586350B1 (fr) *	1985-08-22	1992-05-15	Colgate Palmolive Co	Composition pharmaceutique a base de peroxodiphosphate pour l'inhibition de la secretion d'hormone parathyroidienne
DE4201858A1 (de) *	1992-01-24	1993-07-29	Renschler Aloys Dr Med	Mittel zur behandlung maligner zellen
NO20024880L (no) *	2002-03-19	2003-09-22	Per Hamre	Sammensetning inneholdende fosfat

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4041149A (en) *	1976-01-12	1977-08-09	Colgate-Palmolive Company	Composition and method of controlling and preventing mouth odor
US4430325A (en) *	1981-12-23	1984-02-07	Colgate-Palmolive Company	Topical treatment of skin lesions
DK168191B1 (da) *	1984-06-27	1994-02-28	Colgate Palmolive Co	Anvendelse af peroxydiphosphater til fremstilling af farmaceutiske tabletter eller farmaceutiske vandige opløsninger
US4975423A (en) *	1984-06-27	1990-12-04	Colgate-Palmolive Company	Inhibition of tumor development

1986
- 1986-08-16 DE DE19863627759 patent/DE3627759A1/de not_active Ceased
- 1986-08-18 FR FR868611812A patent/FR2586351B1/fr not_active Expired - Lifetime
- 1986-08-19 SE SE8603486A patent/SE468626B/sv not_active IP Right Cessation
- 1986-08-19 IT IT48389/86A patent/IT1196587B/it active
- 1986-08-21 CA CA000516466A patent/CA1282004C/fr not_active Expired - Lifetime
- 1986-08-22 DK DK402086A patent/DK168513B1/da not_active IP Right Cessation
- 1986-08-22 NL NL8602140A patent/NL8602140A/nl not_active Application Discontinuation
- 1986-08-22 CH CH3377/86A patent/CH670046A5/de not_active IP Right Cessation
- 1986-08-22 GB GB8620482A patent/GB2180451B/en not_active Expired
- 1986-08-22 BE BE0/217073A patent/BE905319A/fr not_active IP Right Cessation
1992
- 1992-10-14 SG SG1088/92A patent/SG108892G/en unknown
1993
- 1993-01-07 HK HK5/93A patent/HK593A/xx unknown

Also Published As

Publication number	Publication date
IT1196587B (it)	1988-11-16
SE8603486L (sv)	1987-02-23
FR2586351B1 (fr)	1991-10-18
CH670046A5 (fr)	1989-05-12
GB2180451A (en)	1987-04-01
SG108892G (en)	1992-12-24
CA1282004C (fr)	1991-03-26
SE8603486D0 (sv)	1986-08-19
HK593A (en)	1993-01-15
GB2180451B (en)	1989-10-18
BE905319A (fr)	1987-02-23
DK402086D0 (da)	1986-08-22
DK168513B1 (da)	1994-04-11
DE3627759A1 (de)	1987-03-19
FR2586351A1 (fr)	1987-02-27
IT8648389A0 (it)	1986-08-19
SE468626B (sv)	1993-02-22
DK402086A (da)	1987-02-23
GB8620482D0 (en)	1986-10-01

Legal Events

Date	Code	Title
1993-09-01	BA	A request for search or an international-type search has been filed
1993-10-01	BB	A search report has been drawn up
1994-03-01	BC	A request for examination has been filed
1995-04-03	BV	The patent application has lapsed

Publication	Publication Date	Title
EP0139535B1 (fr)	1990-12-27	Compositions pour combattre la toxaemie
EP0226332B1 (fr)	1992-03-25	Compositions vétérinaires
JP4700808B2 (ja)	2011-06-15	フルボ酸、および種々の状態の処置におけるその使用
EP0139534A2 (fr)	1985-05-02	Compositions pour le traitement prophylactiques de l'ostéite et de l'ostéomyélite
US10973787B2 (en)	2021-04-13	Bactericidal and virucidal pharmaceutical composition
NL8602140A (nl)	1987-03-16	Werkwijze voor het verhinderen van een hypotensieve shock en gelokaliseerde botresorptie veroorzaakt door bacteriele endotoxinen.
KR0143410B1 (ko)	1998-07-15	B형 비루스성 간염치료용 제약학적 조성물
CN1328465A (zh)	2001-12-26	膦酰基甲酸衍生物治疗感染的用途
US5034383A (en)	1991-07-23	Inactivation of bacterial endotoxins using peroxy-diphosphate compoounds
US4975423A (en)	1990-12-04	Inhibition of tumor development
DK168191B1 (da)	1994-02-28	Anvendelse af peroxydiphosphater til fremstilling af farmaceutiske tabletter eller farmaceutiske vandige opløsninger
JPH10504279A (ja)	1998-04-28	ウイルス感染症及び場合により炎症の予防及び／又は治療用医薬組成物並びにそれらの治療方法
JPS5946208A (ja)	1984-03-15	抗菌性組成物
RU2095063C1 (ru)	1997-11-10	Фармацевтическая композиция, обладающая антибактериальным действием
JPS62123121A (ja)	1987-06-04	細菌内毒素の不活化方法
HU203666B (en)	1991-09-30	Process for producing pharmaceutical compositions containing dipyridamol for improving antiviral activity of interferone-alpha
US20030109505A1 (en)	2003-06-12	Medicament for the treatment of diseases caused by parasitic protozoa
RU2115415C1 (ru)	1998-07-20	Твердая дозированная форма для перорального применения, обладающая противовирусной активностью (варианты)
CA1307740C (fr)	1992-09-22	Preparation pharmaceutique et methode permettant d'inhiber la replication du htlv-iii (sida)
US3772438A (en)	1973-11-13	Antibiotic compositions containing coumermycin
US20200289412A1 (en)	2020-09-17	Bioenhanced spirulina lozenge formulation
NL8403948A (nl)	1985-07-16	Antibacteriele geneesmiddelsamenstelling.
RU1751890C (ru)	1995-09-20	Препарат для лечения колибактериоза телят "ромиксин"
NL8602139A (nl)	1987-03-16	Remming van parathyroide hormoonsecretie.
US5028439A (en)	1991-07-02	Inhibition of parathyroid hormone secretion